tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Cogent Biosciences initiated with a Strong Buy at Raymond James

Raymond James initiated coverage of Cogent Biosciences (COGT) with a Strong Buy rating and $30 price target The firm thinks the company’s lead asset bezuclastinib possesses best-in-class potential in the “large and expanding” non-advanced systemic mastocytosis market. Key opinion leaders believe bezuclastinib possesses a differentiated profile, offering a meaningful efficacy and safety benefit, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1